AbangeLabsSweden reimbursed Lyvdelzi after reviewing a MAIC-based comparison in PBC, a useful HTA signal for indirect evidence strategy. https://www.mattheneus.com/editorial/tlv-lyvdelzi-seladelpar-pbc-general-reimbursement-maic-response-elative-2026-01-27 #HTA #MAIC #EvidenceSynthesis #Pharma
Sweden reimburses Lyvdelzi for primary biliary cholangitis after matched indirect comparison against Iqirvo
Sweden's Dental and Pharmaceutical Benefits Agency (TLV) has granted general reimbursement for seladelpar (Lyvdelzi) in primary biliary cholangitis (PBC), a health technology assessment (HTA) decision that reviewed RESPONSE and ELATIVE phase III evidence through a matching-adjusted indirect comparison (MAIC) and a cost comparison versus Iqirvo.